M. H. Trivedi, A. J. Rush, S. R. Wisniewski, A. A. Nierenberg, D. Warden et al., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice, Am J Psychiatry. janv, vol.163, issue.1, pp.28-40, 2006.

A. J. Rush, M. H. Trivedi, S. R. Wisniewski, J. W. Stewart, A. A. Nierenberg et al., Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression, N Engl J Med. 23 mars, vol.354, issue.12, pp.1231-1273, 2006.

E. S. Paykel, R. Ramana, Z. Cooper, H. Hayhurst, J. Kerr et al., Residual symptoms after partial remission: an important outcome in depression, Psychol Med. nov, vol.25, issue.6, pp.1171-80, 1995.

M. B. Keller, Relapse in Major Depressive Disorder: Analysis With the Life Table, Archives of General Psychiatry. 1 août, vol.39, issue.8, p.911, 1982.

S. Zhou, Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II, Clin Pharmacokinet, vol.48, issue.12, pp.761-804, 2009.

J. Kirchheiner, K. Nickchen, M. Bauer, M. Wong, J. Licinio et al., Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry. mai, vol.9, issue.5, pp.442-73, 2004.

E. Spina and J. De-leon, Clinical applications of CYP genotyping in psychiatry, J Neural Transm (Vienna). janv, vol.122, issue.1, pp.5-28, 2015.

J. J. Swen, M. Nijenhuis, A. De-boer, L. Grandia, A. H. Maitland-van-der-zee et al., Pharmacogenetics: from bench to byte--an update of guidelines, Clin Pharmacol Ther. mai, vol.89, issue.5, pp.662-73, 2011.

D. Food and . Administration, Drugs. Table of pharmacogenomic biomarkers in drug labeling, 2016.

S. Quaranta, J. Dupouey, R. Colle, and C. Verstuyft, Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation -recommendations from the French National Network of Pharmacogenetics, Therapie. avr, vol.72, issue.2, pp.311-319, 2017.

J. K. Hicks, J. J. Swen, C. F. Thorn, K. Sangkuhl, E. D. Kharasch et al., Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants, Clin Pharmacol Ther. mai, vol.93, issue.5, pp.402-410, 2013.

J. Hicks, J. Bishop, K. Sangkuhl, D. Müller, Y. Ji et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, Clinical Pharmacology & Therapeutics. août, vol.98, issue.2, pp.127-161, 2015.

P. Bradley, M. Shiekh, V. Mehra, K. Vrbicky, S. Layle et al., Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility, Journal of Psychiatric Research. janv, vol.96, pp.100-107, 2018.

J. Espadaler, M. Tuson, J. M. Lopez-ibor, F. Lopez-ibor, and M. I. Lopez-ibor, Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis, CNS Spectrums. août, vol.22, issue.04, pp.315-339, 2017.

D. K. Hall-flavin, J. G. Winner, J. D. Allen, J. J. Jordan, R. S. Nesheim et al., Using a pharmacogenomic algorithm to guide the treatment of depression. Translational Psychiatry, vol.2, pp.172-172, 2012.

D. K. Hall-flavin, J. G. Winner, J. D. Allen, J. M. Carhart, B. Proctor et al., Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting: Pharmacogenetics and Genomics, vol.23, pp.535-583, 2013.

G. Ruaño, B. L. Szarek, D. Villagra, K. Gorowski, M. Kocherla et al., Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder, Biomarkers in Medicine. juin, vol.7, issue.3, pp.429-468, 2013.

A. Group, V. Pérez, A. Salavert, J. Espadaler, M. Tuson et al., Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial, BMC Psychiatry. déc, vol.17, issue.1, 2017.

J. G. Winner, J. M. Carhart, C. A. Altar, S. Goldfarb, J. D. Allen et al., Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Current Medical Research and Opinion. 2 sept, vol.31, pp.1633-1676, 2015.

C. Lanni, M. Racchi, and S. Govoni, Do we need pharmacogenetics to personalize antidepressant therapy?, Cellular and Molecular Life Sciences. sept, vol.70, issue.18, pp.3327-3367, 2013.

C. Fabbri and A. Serretti, Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies, Neuroscience Letters, 2018.

S. Horstmann and E. B. Binder, Pharmacogenomics of antidepressant drugs, Pharmacology & Therapeutics. oct, vol.124, issue.1, pp.57-73, 2009.

P. Verbeurgt, T. Mamiya, and J. Oesterheld, How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping, Pharmacogenomics, vol.15, issue.5, pp.655-665, 2014.

D. J. Conrado, H. L. Rogers, I. Zineh, and M. A. Pacanowski, Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels, Pharmacogenomics. janv, vol.14, issue.2, pp.215-238, 2013.

M. Gex-fabry, C. B. Eap, B. Oneda, N. Gervasoni, A. Bondolfi et al., CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response, Ther Drug Monit. août, vol.30, issue.4, pp.474-82, 2008.

C. Normann, M. Hörn, B. Hummel, H. Grunze, and J. Walden, Paroxetine in major depression: correlating plasma concentrations and clinical response, Pharmacopsychiatry. mai, vol.37, issue.3, pp.123-129, 2004.

V. Florio, S. Porcelli, A. Saria, A. Serretti, and A. Conca, Escitalopram plasma levels and antidepressant response, European Neuropsychopharmacology. sept, vol.27, issue.9, pp.940-944, 2017.

C. Charlier, E. Pinto, M. Ansseau, and G. Plomteux, Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients, J Psychopharmacol (Oxford). déc, vol.16, issue.4, pp.369-72, 2002.

Y. Suzuki, N. Fukui, K. Sawamura, T. Sugai, J. Watanabe et al., Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression, J Clin Psychopharmacol. juin, vol.28, issue.3, pp.325-333, 2008.

K. E. Tansey, M. Guipponi, X. Hu, E. Domenici, G. Lewis et al., Contribution of common genetic variants to antidepressant response, Biol Psychiatry. 1 avr, vol.73, issue.7, pp.679-82, 2013.

V. De-carlo, R. Calati, and A. Serretti, Socio-demographic and clinical predictors of non-response/nonremission in treatment resistant depressed patients: A systematic review, Psychiatry Research. juin, vol.240, pp.421-451, 2016.

C. Bonvicini, A. Minelli, C. Scassellati, M. Bortolomasi, M. Segala et al., Serotonin transporter gene polymorphisms and treatment-resistant depression, Prog Neuropsychopharmacol Biol Psychiatry. 16 août, vol.34, issue.6, pp.934-943, 2010.

S. Anttila, K. Huuhka, M. Huuhka, R. Rontu, M. Hurme et al., Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression, Journal of Neural Transmission. août, vol.114, issue.8, pp.1065-1073, 2007.

Y. Kim and K. Na, Role of glutamate receptors and glial cells in the pathophysiology of treatmentresistant depression, Progress in Neuro-Psychopharmacology and Biological Psychiatry. oct, vol.70, pp.117-143, 2016.

E. J. Peters, S. L. Slager, J. B. Kraft, G. D. Jenkins, M. S. Reinalda et al., Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample, PLoS ONE. 2 avr, vol.3, issue.4, p.1872, 2008.

A. Serretti, R. Calati, I. Massat, S. Linotte, S. Kasper et al., Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients, International Clinical Psychopharmacology. sept, vol.24, issue.5, pp.250-256, 2009.

M. Zimmerman, M. A. Posternak, and I. Chelminski, Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression, Journal of Psychiatric Research, vol.38, issue.6, pp.577-82, 2004.

D. Souery, J. Amsterdam, C. Demontigny, Y. Lecrubier, S. Montgomery et al., Treatment resistant depression: methodological overview and operational criteria, Eur. Neuropsychopharmacol, vol.9, pp.83-91, 1999.

M. Mathys and B. G. Mitchell, Targeting treatment-resistant depression, J. Pharm. Pract, vol.24, pp.520-533, 2011.

A. Ks, Treatment-resistant depression: therapeutic trends, challenges, and future directions, Patient Prefer. Adherence, vol.6, pp.369-388, 2012.

G. I. Keitner and A. K. Mansfield, Management of treatment-resistant depression, Psychiatr. Clin. N. Am, vol.35, pp.249-265, 2012.

A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart et al., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report, Am. J. Psychiatry, vol.163, pp.1905-1917, 2006.

B. N. Gaynes, D. Warden, M. H. Trivedi, S. R. Wisniewski, M. Fava et al., What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression, Psychiatr. Serv, vol.60, pp.1439-1445, 2009.

E. Jenkins and E. M. Goldner, Approaches to understanding and addressing treatment-resistant depression: a scoping review, Depress. Res. Treat, p.469680, 2012.

R. A. Cain, Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study: practical outcomes and implications for depression treatment in primary care, Prim. Care, vol.34, pp.505-519, 2007.

M. T. Berlim, M. P. Fleck, and G. Turecki, Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview, Ann. Med, vol.40, pp.149-159, 2008.

M. T. Berlim and G. Turecki, What is the meaning of treatment resistant/ refractory major depression (TRD)? A systematic review of current randomized trials, Eur. Neuropsychopharmacol, vol.17, pp.696-707, 2007.

G. S. Malhi, G. B. Parker, J. Crawford, K. Wilhelm, and P. B. Mitchell, Treatment-resistant depression: resistant to definition?, Acta.Psychiatr.Scand, vol.112, issue.4, pp.302-309, 2005.

R. S. Mcintyre, M. Filteau, L. Martin, S. Patry, A. Carvalho et al., Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach, Journal of Affective Disorders. mars, vol.156, pp.1-7, 2014.

E. S. Paykel, Achieving gains beyond response, 2000.

L. L. Judd, Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse, 1998.

A. Fekadu, S. C. Wooderson, K. Markopoulo, C. Donaldson, A. Papadopoulos et al., What happens to patient with treatment-resistant depression?, J Of Affective Disorder, vol.116, pp.4-11, 2006.

P. E. Greenberg, R. C. Kessler, H. G. Birnbaum, S. A. Leong, S. W. Lowe et al., The economic burden of depression in the United States: how did it change between 1990 and, J. Clin. Psychiatry, vol.64, pp.1465-1475, 2000.

C. M. Thomas and M. Morris, Cost of depression among adults in England in 2000, Br. J. Psychiatry, vol.183, pp.514-519, 2003.

D. Bennabi, B. Aouizerate, W. El-hage, O. Doumy, F. Moliere et al., Risk factors for treatment resistance in unipolar depression: A systematic review, J. Of Affective Disorder, vol.171, pp.137-141, 2015.

D. Souery, P. Oswald, I. Massat, U. Bailer, J. Bollen et al., Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study, J. Clin. Psychiatry, vol.68, pp.1062-1070, 2007.

, Clinical Pharmacogenetics Implementation Consortium, CPIC Guidelines, 2014.

V. Pérez, A. Salavert, J. Espadaler, M. Tuson, J. Saiz-ruiz et al., Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial, BMC Psychiatry, vol.17, p.250, 2017.

, Declaration of Helsinki from the World Medical Association (WMA) -Ethical principles for medical research involving human subjects. 64th WMA General Assembly, 2013.

, International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, 1996.

M. Hamilton, A rating scale for depression, J Neurol Neurosurg Psychiatry. févr, vol.23, pp.56-62, 1960.

S. A. Montgomery and M. Asberg, A new depression scale designed to be sensitive to change, The British Journal of Psychiatry. 1 avr, vol.134, issue.4, pp.382-391, 1979.

C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier et al., AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update, Pharmacopsychiatry. sept, vol.44, issue.06, pp.195-235, 2011.

A. K. Daly, V. M. Steen, K. S. Fairbrother, and J. R. Idle, Methods in Enzymology, pp.199-210, 1996.

J. Blaisdell, H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter et al., Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. déc, vol.12, issue.9, pp.703-714, 2002.

H. Fukushima-uesaka, Y. Saito, K. Maekawa, S. Ozawa, R. Hasegawa et al., Genetic variations and haplotypes of CYP2C19 in a Japanese population, Drug Metab Pharmacokinet. août, vol.20, issue.4, pp.300-307, 2005.

, Pharmacogene Variation Consortium. Banque de données en pharmacogénétique

M. B. Keller, Relapse in Major Depressive Disorder: Analysis With the Life Table, Archives of General Psychiatry. 1 août, vol.39, issue.8, p.911, 1982.

R. Y. Qumsieh, B. R. Ali, Y. M. Abdulrazzaq, O. Osman, N. A. Akawi et al., Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis, PLoS ONE, vol.6, issue.12, p.28943, 2011.

, Clinical Pharmacogenetics Implementation Consortium (CPIC)

S. C. Sim, C. Risinger, M. Dahl, E. Aklillu, M. Christensen et al., A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther. janv, vol.79, issue.1, pp.103-116, 2006.

A. De-vos, J. Van-der-weide, and H. M. Loovers, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients, Pharmacogenomics J. oct, vol.11, issue.5, pp.359-67, 2011.

D. Sibbing, D. Gebhard, W. Koch, S. Braun, J. Stegherr et al., Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy, J Thromb Haemost JTH. août, vol.8, issue.8, pp.1685-93, 2010.

J. K. Hicks, K. Sangkuhl, J. J. Swen, V. L. Ellingrod, D. J. Müller et al., Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update, Clin Pharmacol Ther, 2016.

K. R. Crews, A. Gaedigk, H. M. Dunnenberger, J. S. Leeder, T. E. Klein et al., Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update, Clin Pharmacol Ther. avr, vol.95, issue.4, pp.376-82, 2014.

S. A. Scott, K. Sangkuhl, C. M. Stein, J. Hulot, J. L. Mega et al., Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update, Clin Pharmacol Ther. sept, vol.94, issue.3, pp.317-340, 2013.

A. Gaedigk, S. D. Simon, R. E. Pearce, L. D. Bradford, M. J. Kennedy et al., The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype, Clin Pharmacol Ther. févr, vol.83, issue.2, pp.234-276, 2008.

J. De-leon, S. C. Armstrong, and K. L. Cozza, Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19, Psychosomatics. févr, vol.47, issue.1, pp.75-85, 2006.

W. J. Youden, Index for rating diagnostic tests, Cancer, vol.3, issue.1, pp.32-35, 1950.

K. Aoki, J. Misumi, T. Kimura, W. Zhao, and T. Xie, Evaluation of cutoff levels for screening of gastric cancer using serum pepsinogens and distributions of levels of serum pepsinogen i, ii and of pg i/pg ii ratios in a gastric cancer case-control study, Journal of epidemiology, vol.7, issue.3, pp.143-151, 1997.

M. Greiner, D. Pfeiffer, and R. D. Smith, Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Preventive veterinary medicine, vol.45, pp.23-41, 2000.

C. E. Metz, Basic principles of roc analysis, Seminars in nuclear medicine, vol.8, pp.283-298, 1978.

J. Vermont, J. L. Bosson, P. Francois, C. Robert, A. Rueff et al., Strategies for graphical threshold determination, Computer methods and Programs in Biomedicine, vol.35, issue.2, pp.141-150, 1991.

E. A. Boyle, Y. I. Li, and J. K. Pritchard, An Expanded View of Complex Traits: From Polygenic to Omnigenic, Cell, vol.169, pp.1177-1186, 2017.